Risk Factors for Carbapenem-Resistant <i>Enterobacterales</i> Clinical Treatment Failure-Reference-Cited by-同舟云学术

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure

Published:2023-02-14 Issue:1 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Rebold Nicholas¹²^ORCID,Lagnf Abdalhamid M.¹²,Alosaimy Sara¹²,Holger Dana J.¹²,Witucki Paige¹,Mannino Andrew¹,Dierker Michelle¹,Lucas Kristen¹²,Kunz Coyne Ashlan J.¹²^ORCID,El Ghali Amer¹²,Caniff Kaylee E.¹²,Veve Michael P.¹³^ORCID,Rybak Michael J.¹²⁴⁵^ORCID

Affiliation:

1. College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA

2. Anti-Infective Research Laboratory, Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA

3. Department of Pharmacy, Henry Ford Hospital, Henry Ford Health System, Detroit, Michigan, USA

4. Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA

5. School of Medicine, Wayne State University, Detroit, Michigan, USA

Abstract

This work compares carbapenem-resistant Enterobacterales (CRE) infections using patient, clinical, and treatment variables to understand which characteristics are associated with the highest risk of clinical failure. Knowing which risk factors are associated with CRE infection failure can provide clinicians better prognostic and targeted interventions.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02647-22

Reference30 articles.

1. Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

2. National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States

3. Antibiotic resistance threats in the United States, 2019

4. Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017

5. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parallel biosensor platform for the detection of carbapenemase-producing E. coli in spiked food and water samples;Food Control;2024-09

2. Clinical risk factors and outcomes of carbapenem-resistant Escherichia coli nosocomial infections in a Chinese teaching hospital: a retrospective study from 2013 to 2020;Microbiology Spectrum;2024-07-02

3. Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime–avibactam: A prospective multicentric cohort study;Journal of Global Antimicrobial Resistance;2024-03

4. Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment;Antimicrobial Agents and Chemotherapy;2023-11-15

5. Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance;Infection;2023-06-06